PT3707261T - Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos - Google Patents

Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos

Info

Publication number
PT3707261T
PT3707261T PT187971627T PT18797162T PT3707261T PT 3707261 T PT3707261 T PT 3707261T PT 187971627 T PT187971627 T PT 187971627T PT 18797162 T PT18797162 T PT 18797162T PT 3707261 T PT3707261 T PT 3707261T
Authority
PT
Portugal
Prior art keywords
chemotherapeutics
protease
fusion
carriers
proteins based
Prior art date
Application number
PT187971627T
Other languages
English (en)
Original Assignee
Thena Biotech S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thena Biotech S R L filed Critical Thena Biotech S R L
Publication of PT3707261T publication Critical patent/PT3707261T/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187971627T 2017-11-06 2018-11-05 Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos PT3707261T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT201700116184 2017-11-06

Publications (1)

Publication Number Publication Date
PT3707261T true PT3707261T (pt) 2022-07-13

Family

ID=61581399

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187971627T PT3707261T (pt) 2017-11-06 2018-11-05 Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos

Country Status (11)

Country Link
US (1) US11987604B2 (pt)
EP (1) EP3707261B1 (pt)
JP (1) JP7297745B2 (pt)
CN (1) CN111328346B (pt)
CA (1) CA3082076A1 (pt)
DK (1) DK3707261T3 (pt)
EA (1) EA202090897A1 (pt)
ES (1) ES2923152T3 (pt)
PL (1) PL3707261T3 (pt)
PT (1) PT3707261T (pt)
WO (1) WO2019087155A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012296951B2 (en) * 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
PL3707261T3 (pl) 2017-11-06 2022-09-12 Thena Biotech S.r.l. Białka fuzyjne na bazie ludzkiej ferrytyny i peptydów możliwych do cięcia za pomocą proteazy oraz ich zastosowanie jako nośników chemioterapeutycznych
CN114616241A (zh) * 2019-07-12 2022-06-10 昆山新蕴达生物科技有限公司 基于铁蛋白重链亚基的药物载体
CN116897162A (zh) * 2021-02-25 2023-10-17 昆山新蕴达生物科技有限公司 铁蛋白重链亚基突变体及其应用
CN115137839A (zh) * 2021-03-30 2022-10-04 南京纳么美科技有限公司 靶向-共装载亲/疏水药物的铁蛋白笼纳米载体及其应用
CN113476588B (zh) * 2021-07-06 2022-11-22 武汉大学 靶向乳腺癌的多功能纳米颗粒、其制备方法及其应用
CN114230671B (zh) * 2021-11-18 2023-12-01 中国科学院武汉病毒研究所 寨卡病毒重组蛋白疫苗及其制备方法
CN116410333A (zh) * 2021-12-31 2023-07-11 四川大学 一类促凋亡铁蛋白纳米粒和应用
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途
CN115181733B (zh) * 2022-05-26 2023-11-21 中国农业科学院北京畜牧兽医研究所 相对定量分析猪铁蛋白重链fth1的肽段组合物及应用
CN114886873B (zh) * 2022-06-15 2023-03-24 南京林业大学 一种负载sn-38的铁蛋白纳米粒及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871252A (zh) * 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
BR112015004734A2 (pt) * 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
US10640775B2 (en) * 2014-09-30 2020-05-05 Thena Biotech S.r.l. Fusion protein, nanoparticle composed of a plurality of monomers of said fusion protein, and uses thereof
PL3707261T3 (pl) 2017-11-06 2022-09-12 Thena Biotech S.r.l. Białka fuzyjne na bazie ludzkiej ferrytyny i peptydów możliwych do cięcia za pomocą proteazy oraz ich zastosowanie jako nośników chemioterapeutycznych

Also Published As

Publication number Publication date
JP2021509104A (ja) 2021-03-18
US11987604B2 (en) 2024-05-21
PL3707261T3 (pl) 2022-09-12
CN111328346B (zh) 2023-06-23
DK3707261T3 (da) 2022-07-11
WO2019087155A1 (en) 2019-05-09
ES2923152T3 (es) 2022-09-23
CA3082076A1 (en) 2019-05-09
US20210403515A1 (en) 2021-12-30
EP3707261B1 (en) 2022-05-04
CN111328346A (zh) 2020-06-23
EA202090897A1 (ru) 2020-08-28
EP3707261A1 (en) 2020-09-16
JP7297745B2 (ja) 2023-06-26

Similar Documents

Publication Publication Date Title
PT3707261T (pt) Proteínas de fusão à base de ferritina humana e péptidos cliváveis por protéase e a sua utilização como veículos quimioterapêuticos
AU201810677S (en) Skin treatment article
AU201714140S (en) Skin treatment article
AU201714143S (en) Skin treatment article
AU201810686S (en) Skin treatment article
LT3235830T (lt) Interleukino 15 baltymų kompleksas ir jo naudojimas
IL253872A0 (en) Unnatural semaphorins 3 and their medicinal use
AU201810683S (en) Skin treatment article
AU201810685S (en) Skin treatment article
AU201714141S (en) Skin treatment article
EP3405222C0 (en) NEW POLYPEPTIDES AND THEIR MEDICAL USES
AU201810689S (en) Skin treatment article
SG11201909751TA (en) Human alpha fetoprotein-specific t cell receptors and uses thereof
ZA201704726B (en) Peptides and their use in the treatment of skin
AU201810687S (en) Skin treatment article
EP3587440A4 (en) HUMAN HIGH PROTEIN INFFINITY PD-L1 PEPTIDE AND USES THEREOF
SG11202006669RA (en) Peptides and uses thereof
HK1253725A1 (zh) 新型抗微生物肽及其用途
IL272050B1 (en) Synthetic proteins and their therapeutic uses
SG11202004529XA (en) Transformed human cell and use thereof
PT3680299T (pt) Tinta mate e material de pele
IL272164A (en) 3-acyl-benzamides and their use as herbicides
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
AU201810676S (en) Skin treatment article
HUE062120T2 (hu) Peptid-származék és alkalmazása